BridgeBio Pharma Inc. (BBIO) Misses Q3 EPS by 29c

BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q3 EPS of ($1.08), $0.29 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $4.09 million versus the consensus estimate of $3.62 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• JPMorgan Downgrades Guangdong Marubi Biotechnology Co Ltd (603983:CH) to Underweight
• Raymond James Reiterates Outperform Rating on Progressive Corp. (PGR)